RxDoctor Payments Data

Wendy Tokarz

Nurse Practitioner · Lake Forest, ILNPI 1528676467

Payments from drug & device makers

$1,177in general payments, 2019–2025

Across 63 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$336
  • Boehringer Ingelheim$213
  • Novo Nordisk$210
  • Xeris Pharmaceuticals, Inc.$160
  • Sanofi-aventis U.S. LLC$83
  • Abbott$58
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$96782%
  • Education$21018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$45,543
Medicare patients
172
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$122,796
JardianceEmpagliflozin52$77,624
MounjaroTirzepatide53$69,431
TrulicityDulaglutide41$48,112
Fiasp FlextouchInsulin Aspart (Niacinamide)16$26,857
FarxigaDapagliflozin Propanediol14$12,585
Tresiba Flextouch U-100Insulin Degludec18$11,542
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,558
Novolog FlexpenInsulin Aspart27$7,307
Lyumjev Kwikpen U-100Insulin Lispro-Aabc11$6,618
Humalog Kwikpen U-100Insulin Lispro37$5,847
Nano 2nd Gen Pen NeedlePen Needle, Diabetic58$5,574
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$3,901
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic14$1,170
Metformin Hcl ErMetformin Hcl62$981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$210$122,79690 claims
Boehringer IngelheimJardiance$213$77,62452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Lake Forest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →